Loading clinical trials...
Loading clinical trials...
A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor
Conditions
Interventions
SAGE-217
SAGE-217
+1 more
Locations
26
United States
Sage Investigational Site
Anniston, Alabama, United States
Sage Investigational Site
Little Rock, Arkansas, United States
Sage Investigational Site
Rogers, Arkansas, United States
Sage Investigational Site
Cerritos, California, United States
Sage Investigational Site
Fountain Valley, California, United States
Sage Investigational Site
Oceanside, California, United States
Start Date
March 24, 2017
Primary Completion Date
November 22, 2017
Completion Date
December 5, 2017
Last Updated
November 28, 2023
NCT07417280
NCT04212780
NCT03984643
NCT01581580
NCT07056361
NCT01734122
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions